78183-15-0

Usage

Uses

Used in Pharmaceutical Industry:
6,7-dihydro-5H-cyclopenta[b]pyridin-4-amine is used as a pharmaceutical intermediate for the development of new drugs. Its unique structure and potential biological activities make it a promising candidate for the treatment of various diseases.
Used in Medicinal Chemistry Research:
6,7-dihydro-5H-cyclopenta[b]pyridin-4-amine is used as a research compound in medicinal chemistry to study its potential biological activities and pharmacological properties. Further studies are needed to fully understand its potential applications in various medical treatments.
Used in Neuroscience Research:
6,7-dihydro-5H-cyclopenta[b]pyridin-4-amine is used as a research tool in neuroscience to explore its potential effects on the nervous system and its possible use in the treatment of neurological disorders.
Used in Cancer Research:
6,7-dihydro-5H-cyclopenta[b]pyridin-4-amine is used as a research compound in cancer research to investigate its potential anti-cancer properties and its possible use in the development of new cancer therapies.

Upstream product

• 533-37-9 2,3-cyclopentenopyridine 
• 90685-58-8 6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide 
• 126259-73-2 4-nitro-6,7-dihydro-5H-cyclopenta[b]pyridine-1-oxide 

Downstream Products

• 881204-65-5 4-bromo-6,7-dihydro-5H-cyclopenta[b]pyridine 

Relevant academic research and scientific papers

MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS

The invention provides compounds of formula (I) or pharmaceutically acceptable salt thereof wherein ring A represents group A-I, A-II or A-III. Al represents -C(R4a)(R4a)-, -C(R4a)= -N(R4b)-, -N= -O- or -S-; A2 represents -C(R4c)(R4c)-, -C(R4c)= or -0-; A3 represents -C(R4c)(R4c)-, -C(R4c)= or -0-; A4 represents -C(R4a)(R4a)-, -C(R4a)= -N= -O- or -S-; A5 represents -C(R4a)(R4a)-, -C(R4a)= -N(R4b)-, -N= -O- or -S-; A6 represents -C(R4c)(R4c)- or -C(R4c)=; A7 represents -C(R4a)(R4a)-, -C(R4a)= -N= -O- or -S-; A8 represents -C(R4a)(R4a)-, -N(R4b)-, -O- or -S-; A9 represents -C(R4c)(R4c)- or -0-; A10 represents -C(R4c)(R4c)- or -0-; A11 represents -C(R4c)(R4c)- or -0-; A12 represents -C(R4a)(R4a)-, -O- or -S-; wherein group A-I, group A-II and group A-III de not contain adjacent oxygen atoms, adjacent oxygen and sulfur atoms or adjacent oxygen and nitrogen atoms or a moiety selected from the group consisting of N-C-N, N-C-S, S-C-S, O-C-N, O-C-O and O-C-S, wherein in each case the carbon atom in the N-C-N, N-C-S, S-C-S, O-C-N, O-C-O and O-C-S moiety is saturated; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a, R4b and R4c are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.